{
    "clinical_study": {
        "@rank": "92435", 
        "arm_group": [
            {
                "arm_group_label": "Nitric Oxide supplement", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy\n      adults with clinical prehypertension."
        }, 
        "brief_title": "Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults", 
        "condition": "Prehypertension", 
        "condition_browse": {
            "mesh_term": "Prehypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults between the ages of 18 to 80 years\n\n          -  Two blood pressure readings of >/=135/80 mmHg at rest, thus representing\n             prehypertension\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Existence of any significant internal or cardiovascular disease;\n\n          -  Current use of any antihypertensive medication.\n\n          -  Inability to give informed consent, or fill out standard questionnaires or inability\n             to follow up clinically."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937754", 
            "org_study_id": "Neo-4085"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nitric Oxide supplement", 
                "description": "Lozenge consisting of beetroot and 75 mg caffeine", 
                "intervention_name": "Nitric Oxide supplement", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Neo40 Daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Same form factor and flavor as test lozenge but contains no active ingredients", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prehypertension", 
            "Nitric Oxide", 
            "Blood Pressure", 
            "Functional Capacity", 
            "Quality of Life"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beverly Hills", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90211"
                }, 
                "name": "California Medical Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension", 
        "other_outcome": {
            "description": "Participants will fill out a standardized quality of life questionnaire at baseline and again after thirty days during the follow-up appointment. Summary component scores will be recorded and compared.", 
            "measure": "Improvement in Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "overall_official": {
            "affiliation": "California Medical Institute, Cedars Sinai Medical Center", 
            "last_name": "Ernst Schwarz, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.", 
            "measure": "Reduction in Systolic and Diastolic Blood Pressure Readings", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937754"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Neogenis Laboratories", 
            "investigator_full_name": "Dr. Ernst Schwarz", 
            "investigator_title": "Attending Cardiologist, Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participant will take a six minute walk test at baseline and again after thirty days during the follow-up appointment. Achieved distances will be measured and recorded.", 
            "measure": "Improvement in Functional Capacity", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "source": "Neogenis Laboratories", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neogenis Laboratories", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}